

Surface anesthesia of the conjunctiva and cornea after the application of eye drops occurs after 30 seconds and lasts for 15 minutes.
Local anesthesia in ophthalmology:
In 1 ml of eye drops 0.4% is contained.
Active substance: aboutXibuprocaine (in the form of hydrochloride) 4 mg.
Excipients: benzalkonium chloride, boric acid, sodium chloride, disodium edetate, water d / i.
No customer reviews for the moment.
The drug is instilled into the conjunctival sac 1 drop.
Long-term anesthesia (up to 1 h) provides 3-time instillation with an interval of 4-5 minutes.
maybe
Short-term tingling sensation, burning and redness of the conjunctiva, allergic reactions.
Seldom
Keratitis
Individual hypersensitivity to the drug.
Negative or positive effects are not described in the literature with simultaneous administration of oxybuprocaine and other eye drops traditionally used in the conjunctival sac.
It is noted that oxybuprocaine can theoretically reduce the antibacterial activity of sulfonamides.
Clinical experience in the use of the drug during pregnancy and lactation is not enough. The use of Inokain during pregnancy and during breastfeeding is possible only in cases where the expected benefit of therapy for the mother outweighs the potential risk to the fetus or infant.
The drug is intended only for instillation in the conjunctival sac. Do not use for injection.
Not intended for long-term therapy in the complex treatment of eye diseases.
Prolonged, repeated and prolonged use (as well as other local anesthetics) can lead to persistent corneal opacities.
During anesthesia, it is necessary to protect the eye from irritating chemical effects, foreign bodies and friction.
Use in Pediatrics
There is not enough experience in the use of the drug in children. Application of Inokain in children is possible only in cases when the expected benefit of therapy exceeds the risk of possible side effects.